<DOC>
	<DOCNO>NCT02127645</DOCNO>
	<brief_summary>Objective : Recent randomize non-randomized study suggest neoadjuvant radiotherapy follow Transanal Endoscopic Microsurgery ( TEM ) show comparative result abdominal resection pT2 extraperitoneal cancer . As risk lymphnode metastases significant already T1 invasive cancer submucosa infiltration &gt; 1 mm intention investigate T1sm2-3 T2 rectal adenocarcinoma effectiveness combine treatment case series compare result pilot study historical series patient affect T1-T2 rectal cancer underwent anterior resection ( AR ) total mesorectal excision ( TME ) without abdomino-perineal resection ( APR ) neoadjuvant therapy . If equally effective , TEM offer reduction invasiveness treatment , correspond lower morbidity , mortality well quality life .</brief_summary>
	<brief_title>Neoadjuvant Radiotherapy Followed Transanal Endoscopic Microsurgery T1-T2 Extraperitoneal Rectal Cancer</brief_title>
	<detailed_description>Study design : This single centre case series pilot study oncologic result compare historical data collect consist patient treat anterior resection ( AR ) total mesorectal excision ( TME ) without abdomino-perineal resection ( APR ) neoadjuvant radiotherapy . Study population : Patients T1sm2-3 T2 , N0 , G1-G2 , locate 2 12 cm anal verge , health condition permit general anesthesia . Interventions : Neoadjuvant radiotherapy dose 25 Gy ( 5 Gy per day 5 consecutive day ) administer patient . Within 10 day end radiotherapy TEM perform . Primary Endpoint : incidence recurrence 36 month Primary outcome measure ( non-inferiority ) : Local recurrence neoplasia , define presence histologically proven neoplastic tissue either visible recurrent lesion random biopsy , take surveillance endoscopy intervention strategy complete . Patients undergo surveillance endoscopy 3 , 6 , 12 , 18 , 24 36 month independent endoscopist . During surveillance endoscopy local recurrence objectively define Higaki criterion recurrence : tumor appear within clear resection scar ; tumor convergent fold ; tumor nearby clear resection scar ( within 5 mm ) ( 39 ) . Targeted biopsy take histological confirmation ; case apparently heal normal scar without evidence recurrence , biopsy take basis 3 edge scar detect occult recurrent neoplasia . Loco-regional recurrence investigate MRI ( CT MRI contraindicate ) perform 6 , 12 , 24 36 month . Distant metastasis investigated standard follow-up accord local policy . Additional outcome measure : 1 . Complications : subdivide procedural ( treatment ) delay complication ( end procedure ) ; subdivide major ( require additional surgery ) minor ( require endoscopic medical intervention ) complication . During admission patient monitor complication . The following standardized discharge criterion apply : normal intake nutrition ; normal mobility ; absence fever ( &lt; 38Â°C ) ; stable hemoglobin level 1 day ( &lt; 1 mmol/L ) case rectal blood loss . Two week intervention , research fellow contact patient telephone ask occur complication . 2 . Generic disease-specific health relate quality life measure baseline , 2 week , 3 month , 6 month , 1 year follow-up SF-36 , EORTC Q30 , EORTC Q38 Wexner score ( incontinence ) questionnaires . 3 . Measurement anorectal functional outcome anal manometry rectal volumetry ( barostat ) 3 month treatment . Sample size : As pilot study , sample size available Economic evaluation : A cost-effectiveness cost-utility analysis neoadjuvant RT follow TEM extraperitoneal rectal cancer respectively cost per recurrence free patient cost per quality adjust life year primary outcome measure , compare historical series patient underwent surgery without neoadjuvant radiotherapy , perform . Time schedule : 36 month inclusion ( June 1st 2011 - May 31st 2014 ) , 36 month minimum follow-up .</detailed_description>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<criteria>Diagnosed large rectal sessile flat lesion ( type 0Is , 0II 0III accord Paris Classification ) large diameter 2 cm larger11 ( estimate open resection snare ) . low upper border rectal neoplasm locate 2 12 cm anal verge , respectively . Biopsies lesion show neoplastic tissue adenocarcinoma G1G2 histopathological evaluation . Endoscopic ultrasonography ( EUS ) rectal lesion confirm invasion submucosal layer ( uT1sm ) &gt; 1 mm muscle layer ( uT2 ) rule presence lymph node &gt; 1 cm . Pelvic Magnetic Resonance Imaging ( MRI ) ( Computer Tomography ( CT ) MRI contraindicate ) rule outlymph node &gt; 1 cm . ASA ( America Society Anesthesiologists ) status IIII . previous anorectal surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>RADIOTHERAPY</keyword>
	<keyword>TRANSANAL ENDOSCOPIC MICROSURGERY</keyword>
	<keyword>LOCAL EXCISION</keyword>
</DOC>